MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. MM-121 is the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development.

Preclinical data exhibiting MM-121’s impact on multiple cancer models (including lung, ovarian, breast, prostate and renal) were presented at the annual meeting of the American Association for Cancer Research in April 2008.

The Phase 1 trial is being conducted at 3 centers in the United States. For more information on current clinical trials, please go to www.clinicaltrials.gov and type in "MM-121" in the search box.